| DRUG | SUPPLIED | DOSE | COMMENTS |
|---|---|---|---|
| MIRTAZAPINE (Paeds) (Remeron, Remeron RD) Mechanism of action: Norepinephrine agonist/specific serotonin antagonist (NaSSA) antidepressant (not a firstline choice) Ref: 4, 44, 83 Last update: 2021-08-02 |
tablet: 15 mg, 30 mg, 45 mg oral disintegrating tablet: (not stocked at BCCH) 15 mg, 30 mg, 45 mg |
Adolescents/Adults: Initial: 7.5-15 mg PO HS. May increase in 15 mg increments at weekly or greater intervals to maximum dose of 45 mg PO HS. |
A norepinephrine agonist/specific serotonin antagonist (NaSSA) antidepressant (not a firstline choice) Adverse effects include: increased appetite, weight gain, drowsiness/sedation, dry mouth, dizziness, weakness, increased ALT, rare QTc prolongation. Sedation effects are paradoxically stronger at lower doses and less strong at higher doses. Prescribers must be aware of warnings issued by Health Canada regarding the use of antidepressants in pediatric patients. Refer to the Health Canada website. Standard Prescription: Mirtazapine __ mg PO HS |